---
document_datetime: 2024-10-17 11:56:11
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zoledronic-acid-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.8734929
conversion_datetime: 2025-12-19 02:08:28.899615
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zoledronic acid Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0032              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 15/10/2024                          |                                             | SmPC and PL                      |           |
| IA/0031              | B.III.1.a.2 - Submission of a new/updated or                                                                                                                                                   | 20/02/2023                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | of Ph. Eur. Certificate of Suitability to the Ph. Eur. Monograph - Updated certificate an already approved manufacturer                                                                                                                                                                                                                                                                           |            |     |    | deletion relevant from   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|--------------------------|
| IB/0030/G   | This was an application for a group of variations. B.II.d.z - Change in control of the Finished Product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                         | 08/04/2022 | n/a |    | procedure                |
| IAIN/0029/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 08/11/2021 | n/a |    |                          |
| N/0028      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                  | 17/09/2021 |     | PL |                          |
| IB/0026     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                              | 04/05/2021 | n/a |    |                          |

<div style=\"page-break-after: always\"></div>

| IB/0027   | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/04/2021   | n/a        |                                  |         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------|
| IB/0025   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/09/2020   | 22/01/2021 | SmPC, Annex II, Labelling and PL | the MAH |
| IB/0024   | C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/01/2020   | 22/01/2021 |                                  |         |
| IB/0023/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 05/09/2019   | n/a        |                                  |         |

<div style=\"page-break-after: always\"></div>

| specification limits B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.c.2.b - Change in and/or limits of the immediate Addition of a new specification specification with its corresponding B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.4.c - Change to applied during the manufacture of a non-significant in-process B.I.b.2.b - Change in starting material/reagent/intermediate a test procedure for the material/reagent/intermediate, procedure is already authorised B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IA/0022   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                | 08/08/2019   | 09/12/2019   | Annex II and PL                  |                                                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 17/12/2018   | n/a          |                                  |                                                                                                                                                                                                                                                                                    |
| IA/0020   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                | 27/02/2018   | 28/09/2018   | Annex II and PL                  |                                                                                                                                                                                                                                                                                    |
| IB/0019   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation               | 06/10/2017   | 28/09/2018   | SmPC and PL                      |                                                                                                                                                                                                                                                                                    |
| R/0018    | Renewal of the marketing authorisation.                                                                                                                                                                      | 23/03/2017   | 22/05/2017   | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic acid Teva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0017   | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                       | 18/10/2016   | n/a          |                                  |                                                                                                                                                                                                                                                                                    |
| IB/0016   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation               | 25/08/2016   | 22/05/2017   | SmPC and PL                      |                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IAIN/0015   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/12/2015   | 11/02/2016   | SmPC and PL           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|
| IB/0014     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20/10/2015   | 11/02/2016   | SmPC, Annex II and PL |
| IA/0013/G   | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 11/05/2015   | n/a          |                       |

<div style=\"page-break-after: always\"></div>

|           | Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |             | B.I.b.1.b -   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------|
| IB/0012/G | This was an application for a group of variations. Update of sections 4.4 and 4.5 of the SmPC to add information on additive effect of hypocalcaemia- causing medicinal products; Update of section 4.6 of the SmPC to add information for women of child-bearing potential; Update of section 4.8 of the SmPC to change frequency of uveitis (from \"very rare\" to \"rare\"); and Update of section 5.2 of the SmPC to revise the text on plasma protein binding. Furthermore. editorial changes are made to update some adverse reaction terms in section 4.8 of the SmPC according to MedDRA preferred terms. The Package Leaflet is updated accordingly.         | 19/02/2015 | 11/02/2016 | SmPC and PL |               |

<div style=\"page-break-after: always\"></div>

|        | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   |            |            |                                  |                                                                                                   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------|
| T/0011 | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/12/2014 | 19/12/2014 | SmPC, Labelling and PL           |                                                                                                   |
| X/0008 | To include a new pharmaceutical form Annex I_2.(d) Change or addition of a new                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/07/2014 | 01/10/2014 | SmPC, Annex II, Labelling and PL | For further information, please refer to the Assessment Report Zoledronic acid-H-2439-X-08-AR-en. |

<div style=\"page-break-after: always\"></div>

|           | pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0010 | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/04/2014 | 27/06/2014 | Annex II and PL |
| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/03/2014 | 27/06/2014 | SmPC and PL     |
| IA/0007/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or | 16/12/2013 | n/a        |                 |

<div style=\"page-break-after: always\"></div>

|           | changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a test procedure (including replacement or addition)   |            |            |                       |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------|
|           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                 | 16/07/2013 | n/a        |                       | IAIN/0006 |
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                 | 15/07/2013 | 27/06/2014 | SmPC, Annex II and PL |           |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                 | 17/01/2013 | 27/06/2014 | SmPC and PL           |           |
| IB/0002/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                         | 04/12/2012 | n/a        |                       |           |
|           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                  | 19/10/2012 | n/a        |                       | IAIN/0001 |

<div style=\"page-break-after: always\"></div>

| site   |
|--------|